dc.contributor.author | Gogna, Nirdosh Kumar | |
dc.contributor.author | Baxi, Siddhartha | |
dc.contributor.author | Hickey, Brigid | |
dc.contributor.author | Baumann, Kathryn | |
dc.contributor.author | Burmeister, Elizabeth | |
dc.contributor.author | Holt, Tanya | |
dc.date.accessioned | 2020-01-06T04:32:27Z | |
dc.date.available | 2020-01-06T04:32:27Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 0360-3016 | |
dc.identifier.doi | 10.1016/j.ijrobp.2011.12.028 | |
dc.identifier.uri | http://hdl.handle.net/10072/390054 | |
dc.description.abstract | PURPOSE: Local progression, in patients with hormone-refractory prostate cancer, often causes significant morbidity. Pelvic radiotherapy (RT) provides effective palliation in this setting, with most published studies supporting the use of high-dose regimens. The aim of the present study was to examine the role of split-course hypofractionated RT used at our institution in treating this group of patients. METHODS AND MATERIALS: A total of 34 men with locoregionally progressive hormone-refractory prostate cancer, treated with a split course of pelvic RT (45-60 Gy in 18-24 fractions) between 2000 and 2008 were analyzed. The primary endpoints were the response rate and actuarial locoregional progression-free survival. Secondary endpoints included overall survival, compliance, and acute and late toxicity. RESULTS: The median age was 71 years (range, 53-88). Treatment resulted in an overall initial response rate of 91%, a median locoregional progression-free survival of 43 months, and median overall survival of 28 months. Compliance was excellent and no significant late toxicity was reported. CONCLUSIONS: The split course pelvic RT described has an acceptable toxicity profile, is effective, and compares well with other high-dose palliative regimens that have been previously reported. | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofpagefrom | E205 | |
dc.relation.ispartofpageto | E211 | |
dc.relation.ispartofissue | 2 | |
dc.relation.ispartofjournal | International Journal of Radiation Oncology, Biology, Physics | |
dc.relation.ispartofvolume | 83 | |
dc.subject.fieldofresearch | Other physical sciences | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearchcode | 5199 | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.keywords | Science & Technology | |
dc.subject.keywords | Life Sciences & Biomedicine | |
dc.subject.keywords | Radiology, Nuclear Medicine & Medical Imaging | |
dc.subject.keywords | Hormone-refractory prostate cancer | |
dc.title | Split-Course, High-Dose Palliative Pelvic Radiotherapy for Locally Progressive Hormone-Refractory Prostate Cancer | |
dc.type | Journal article | |
dcterms.bibliographicCitation | Gogna, NK; Baxi, S; Hickey, B; Baumann, K; Burmeister, E; Holt, T, Split-Course, High-Dose Palliative Pelvic Radiotherapy for Locally Progressive Hormone-Refractory Prostate Cancer, International Journal of Radiation Oncology, Biology, Physics, 2012, 83 (2), pp. E205-E211 | |
dcterms.dateAccepted | 2011-12-06 | |
dc.date.updated | 2020-01-06T04:30:53Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Baxi, Siddhartha | |